Navigation Links
Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
Date:4/29/2011

SAN DIEGO, April 29, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced it plans to report first quarter 2011 financial results on Friday, May 6, 2011 before the open of the financial markets. The announcement will be followed by a conference call with the investment community at 8:00 a.m. PDT (11:00 a.m. EDT), which will be simultaneously broadcast over the Internet. Management will discuss the financial results and highlights for the first quarter of 2011 and provide a product pipeline update.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

To participate by telephone, please dial 877.407.8037 for domestic callers or 201.689.8037 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company's Web site at www.halozyme.com. Shortly after the call an audio replay will be available on Halozyme's Web site for seven days. A telephone replay will be available by dialing 877.660.6853 from the U.S., or 201.612.7415 for international callers and using account # 367 and ID # 371588.  

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche and Baxter to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, and immunoglobulin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Halozyme Contact  
Robert H. Uhl
Senior Director, Investor Relations
(858) 704-8264
ruhl@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
2. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
3. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
4. Halozyme Therapeutics Realigns Management
5. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
6. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
7. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
8. Halozyme Therapeutics Announces Public Offering of Common Stock
9. Halozyme Provides HYLENEX® Product Reintroduction Update
10. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
11. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
(Date:8/2/2017)... , Aug. 2, 2017 Fenita ... Who as a Pinnacle Lifetime Professional in the ... Account Manager at Turing Pharmaceuticals, AG. Her skills ... and relationship building.                ... than 25 years of experience as a highly ...
(Date:8/2/2017)...  Life Flight Network and PeaceHealth Oregon Network announced they ... and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Flight Network work collaboratively to move patients who require the ... time sensitive emergency exists. ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... CEFEX, ... as adhering to the standards representing best practices in the retirement plan industry. ... practice standard and helps to verify that NFP’s retirement division focuses on putting ...
(Date:8/23/2017)... ... 2017 , ... Arizona Spine & Joint Hospital http://www.azspineandjoint.com ... of High Performing Hospitals by U.S. News & World Report for knee replacement in ... better than the national average in a given procedure or condition.  , A ...
(Date:8/23/2017)... ... 23, 2017 , ... TSC Advantage has been awarded Gold ... Solution Innovations and Security Solution for Government Innovations. Both gold awards recognize TSC ... DHS SAFETY Act-designated enterprise security assessment approach. , The ninth annual Golden Bridge ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... good health is as simple as eating healthy foods. But this well-known piece ... fat, making insulin, or breaking apart carbohydrates—depends not only on properties of the ...
(Date:8/22/2017)... Westerly, RI (PRWEB) , ... August 22, 2017 , ... ... on five acres at picturesque Babcock Cove, recently received training and certification in ... Hill , which has a prestigious five-star rating from the Centers for Medicare and ...
Breaking Medicine News(10 mins):